Vincerx Inc (VINC) News

Form 8-K - Current report

Form 8-K - Current report

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123...

Form PRE 14A - Other preliminary proxy statements

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC TO-I - Tender offer statement by Issuer

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by...